Bitcoin price today: slips below $113k, near 6-wk low despite Fed cut bets
Petersen Floyd F., a director at Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH), executed a sale of 1,000 shares of the company’s common stock on March 6, 2025. The shares were sold at a weighted average price of $27.9863, resulting in a total transaction value of $27,986. The transaction occurs as the stock trades near its 52-week low of $26.98, despite the company’s strong financial health score of "GREAT" according to InvestingPro analysis. This transaction was conducted under a Rule 10b5-1 trading plan, which was adopted by Petersen on November 26, 2024. Following this sale, Petersen retains ownership of 74,409 shares in Amphastar Pharmaceuticals.
The shares were sold in multiple transactions, with prices ranging from $27.66 to $28.295. The company is headquartered in Rancho Cucamonga, California, and specializes in pharmaceutical preparations.
In other recent news, Amphastar Pharmaceuticals reported its fourth-quarter 2024 earnings, which fell short of analyst expectations. The company announced an EPS of $0.92, missing the forecast of $0.97, and revenue of $186.5 million, which was below the anticipated $192.69 million. Amphastar’s annual revenue reached $732 million, marking a 14% increase year-over-year. Despite the revenue growth, the company experienced a decline in gross margins, which dropped to 46.5% from 54% the previous year. Amphastar anticipates flat sales in 2025 but remains hopeful for a return to growth in 2026, focusing on new product launches and expanding its manufacturing capacity. The company also announced a strategic partnership with MannKind (NASDAQ:MNKD) to promote Baximi, enhancing its sales reach in the diabetes care market. In terms of competition, Amphastar faces challenges in maintaining market share for its glucagon and epinephrine products due to increased competition. The company is preparing for potential approvals of four key products in 2025, which could impact its future growth trajectory.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.